Replies to post #252185 on Biotech Values

[vinmantoo]

Re: PFE’s CD47 program

Clinicaltrials.gov shows these active phase-2 or phase-1/2 trials for PFE’s CD47 agent, Maplirpacept (PF-07901801):

PFE also has TRIL's two CD47 blockers TTI-621 and TTI-622 in trials for refractory relapsed multiple myeloma (pahse 1b in combination with daratumumab hyaluronidase-fihj) and for diffuse large B cell lymphoma (randomized phase 2 in combination with pembrolizumab).

Hmm, it looks like Maplirpacept is TTI-622 renamed.


https://www.clinicaltrials.gov/study/NCT05507541?term=TTI-621&rank=4

https://www.clinicaltrials.gov/study/NCT05139225?term=TTI-621&rank=5